A Study of a New Drug in People with Diabetes and Kidney Disease
- Study IRB#:2000041228
- Last Updated:10/23/2026
This study is researching an experimental drug called ALN-ANG3 (called “study drug” in this form). This study is focused on participants who have diabetic kidney disease. The aim of this study is to see how safe and effective the study drug is.
- Age18 years - 80 years
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Romani Osbourne
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877-978-8343 for more information.
Study Location
- Yale University
Eligibility Criteria
At minimum, eligible participants must:
1. Have type 2 diabetes.
2. Show evidence of decreased kidney function.
3. Have no history of kidney disease from a cause other than diabetes.
4. Have been taking a stable dose of a blood pressure medication, such as losartan or lisinopril, for at least three months, or be unable to tolerate these types of medications.
Please get in touch with the study team to learn more.
